Online inquiry

IVTScrip™ mRNA-Human ADRA2A, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK14367MR)

This product GTTS-WK14367MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ADRA2A protein. This product can be used in Lake et al.Science.Ex8-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_000681.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 150
UniProt ID P08913
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADRA2A, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK14367MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK24472MR IVTScrip™ mRNA-Human ARPC5L, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARPC5L
GTTS-WK17857MR IVTScrip™ mRNA-Human AMOTL2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMOTL2
GTTS-WK24177MR IVTScrip™ mRNA-Human ARRDC1, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARRDC1
GTTS-WK11634MR IVTScrip™ mRNA-Human ADGRD1, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADGRD1
GTTS-WK16123MR IVTScrip™ mRNA-Human ANKRD37, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD37
GTTS-WK7433MR IVTScrip™ mRNA-Human ADGRB2, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ADGRB2
GTTS-WK23911MR IVTScrip™ mRNA-Human ASGR2, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASGR2
GTTS-WK28608MR IVTScrip™ mRNA-Human ARHGEF11, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARHGEF11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW